CTLA4 and melanoma: Both address critical and independent pathways of advanced melanoma growth: the mitogen-activated protein (MAP) kinase signaling pathway for vemurafenib [70, 71] and the CTLA-4 signaling pathway for ipillimumab [72, 73].